Mammography vendor Fischer Imaging of Denver reported fiscal 2003 second-quarter revenues of $12.6 million from products and services, a 25% increase compared with $10.1 million in sales in the second quarter of 2002. For the period (end-June 29) the company recorded a net loss of $1.5 million, compared with net income of $18.5 million for the comparable quarter in fiscal 2002.
Fischer said its 2003 second-quarter results include patent litigation settlement income of $900,000, whereas the comparable quarter of 2002 results reflect one-time income of $25 million from the same settlement. In addition, the 2003 second-quarter results reflect a one-time consulting and restatement charge of $800,000, and the second quarter of 2002 results include inventory write-downs and other charges of $5.3 million.
For the first half of its fiscal year, Fischer reported revenue from products and services of $22.8 million, a 6% increase compared with the $21.6 million stated for the first half of 2002. The firm’s operating loss for the 2003 period decreased to $4.5 million from $7.2 million in the comparable 2002 period. Net loss for the 2003 period was $3.5 million, compared with net income of $17.6 million for the comparable six-month period in 2002.
By AuntMinnie.com staff writersOctober 8, 2003
Related Reading
ACR to accredit SenoScan, August 18, 2003
Fischer, Philips to develop mammo/US prototype, August 12, 2003
Fischer goes direct in Europe, August 5, 2003
Fischer offers restated results, July 17, 2003
Fischer responds to SEC inquiry, June 12, 2003
Copyright © 2003 AuntMinnie.com











![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&fit=crop&h=112&q=70&w=112)






